In today’s digital-first environment, organizations generate massive volumes of data from operations, customers, devices, and ...

Data science and analytics are entering a phase of recalibration, where measured contribution outweighs technical ambition. Executive focus has moved ...

MDB rallies after Q4 revenues climb 27% with Atlas growth and new AI tools, though premium valuation and slower expected growth cloud the outlook.

Addressing tool fatigue and the rising demands of AI, industry leaders gathered to share practical approaches for streamlining modern data architectures and accelerating product innovation.

Data strategy competitive advantage depends on a proprietary knowledge base of internal and external data powering predictive ...

SourceFuse partners with Databricks to help enterprises modernize data platforms, unlock AI & GenAI capabilities, ...

In an AI-driven threat landscape, success isn’t measured by preventing every breach. It’s measured by controlling the blast ...

Huawei's view is that the role of storage infrastructure must evolve. Rather than simply archiving information, future ...

Regenxbio (RGNX) hit by FDA CRL for RGX-121; valuation discount, cash runway to 2027, risks vs RGX-202 upside. Click here to ...

As AI adoption accelerated across industries, deploying a chatbot to support a newly launched internal application seemed like a logical decision. However, the application itself challenged ...

REGENXBIO (NASDAQ:RGNX) outlined a slate of near-term clinical catalysts and provided financial updates during its fourth-quarter and year-end 2025 earnings call, emphasizing what management described ...